Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05792163




Registration number
NCT05792163
Ethics application status
Date submitted
28/02/2023
Date registered
31/03/2023
Date last updated
15/12/2023

Titles & IDs
Public title
A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease
Scientific title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of SNP318 in Healthy Adult Participants
Secondary ID [1] 0 0
SNP318-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neurodegenerative Diseases 0 0
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias
Neurological 0 0 0 0
Neurodegenerative diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SNP318 (A)
Treatment: Drugs - Placebo (B)

Experimental: A (SNP318) - Drug: SNP318, Dose level: Start from 1mg for single ascending dose and from 30mg for multiple ascending dose. Dose levels can be adjusted based on emerging safety, tolerability, pharmacokinetics data of previous cohorts.
Dosage form: Capsule Route of administration: Oral

Placebo Comparator: B (Placebo) - Placebo comparator taken by participants randomized to the placebo arm in each cohort in Part 1 and Part 2.


Treatment: Drugs: SNP318 (A)
Capsule for oral administration

Treatment: Drugs: Placebo (B)
Placebo capsules matching the SNP318 capsules
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety and tolerability of SNP318 in healthy adult participants. Assessed by adverse events
Timepoint [1] 0 0
Up to 20 days
Secondary outcome [1] 0 0
Plasma PK parameters of SNP318 in healthy adult participants. Assessed by Maximum concentration (Cmax)
Timepoint [1] 0 0
Up to 20 days
Secondary outcome [2] 0 0
Plasma PK parameters of SNP318 in healthy adult participants. Assessed by Time of maximum concentration observed (Tmax)
Timepoint [2] 0 0
Up to 20 days
Secondary outcome [3] 0 0
Plasma PK parameters of SNP318 in healthy adult participants. Assessed by Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC)
Timepoint [3] 0 0
Up to 20 days
Secondary outcome [4] 0 0
Plasma PK parameters of SNP318 in healthy adult participants. Assessed by Apparent oral clearance (CL/F)
Timepoint [4] 0 0
Up to 20 days
Secondary outcome [5] 0 0
Plasma PK parameters of SNP318 in healthy adult participants. Assessed by Apparent volume of distribution at steady state (Vss/F)
Timepoint [5] 0 0
Up to 20 days
Secondary outcome [6] 0 0
Plasma PK parameters of SNP318 in healthy adult participants. Assessed by Apparent terminal phase half-life (T1/2z)
Timepoint [6] 0 0
Up to 20 days
Secondary outcome [7] 0 0
The concentration of SNP318 in CSF samples in healthy adult participants
Timepoint [7] 0 0
Up to 7 days

Eligibility
Key inclusion criteria
1. Participant must be =18 years of age, at the time of signing the informed consent.

2. Participants who are overtly healthy, in the opinion of the Investigator, as
determined by medical evaluation including medical history, physical examination,
vital signs, ECGs and laboratory tests. Participants who do not qualify based on a
reversible condition or mild intercurrent illness may be re-screened after the
underlying condition is resolved.

3. Body weight between 50.0 and 120.0 kg, inclusive, if male; and between 40.0 and 120.0
kg, inclusive, if female. Body Mass Index within the range =19 and =30 kg/m2
(inclusive), at screening.

4. Female participants who engage in heterosexual intercourse must be of non-childbearing
potential, defined as either surgically sterile (ie, hysterectomy, bilateral
salpingectomy, or bilateral oophorectomy), OR be postmenopausal with at least 1 year
of amenorrhea, OR must be using an established form of highly effective method of
contraception from the time of screening until at least 90 days after the last dose of
study intervention. Female participants must not be lactating and must agree to have
no egg donation plan during the study and for 90 days after the last dose of study
intervention.

5. Male participants must agree to use a condom when sexually active with a female
partner of childbearing potential from screening until at least 90 days after the last
dose of study intervention (or be surgically sterile [ie, vasectomy with
documentation]; or remain abstinent, when this is in line with the preferred and usual
lifestyle). Male participants should also agree not to donate sperm for the duration
of the study and until at least 90 days after the last dose of study intervention.

6. Must be capable of giving signed informed consent which includes compliance with the
requirements and restrictions listed in the informed consent form (ICF) and in this
protocol.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Known hypersensitivity, allergy, intolerance, or idiosyncratic reaction to the study
intervention, or any of the excipients contained in the intervention formulation. If
any history of anaphylaxis or reaction to other agents, discussion with (and approval
by) the Investigator and Sponsor is required.

2. Any concomitant disease, condition, or treatment that could interfere with the conduct
of the study or that would, in the opinion of the Investigator or Sponsor, pose an
unacceptable risk to the participant in the study or interfere with the interpretation
of study data.

3. History of dysphagia or any gastrointestinal disease (including Gilbert's syndrome)
that affects the participants ability to swallow and/or affects drug absorption.

4. Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test at any time
prior to administration of the study intervention if SARS-CoV-2 test is performed.

5. Any clinically significant (at the discretion of the Investigator) abnormalities in
laboratory test results. Total bilirubin value up to 1.5 times the upper normal limit
of normal can be acceptable if associated with normal conjugated bilirubin value
(unless the participant has documented Gilbert's Syndrome).

6. History of immunological disorders, auto-immune disorders, acquired or congenital
immune deficiency, including autoimmune rheumatic disease.

Note: participants with mild asthma controlled with occasional rescue inhaler only (no
chronic therapy; no inhaled corticosteroids), and mild atopic dermatitis controlled
with topic emollients only (no topical corticosteroids) are not excluded.

7. Immunization with any live vaccine within 28 days prior to administration of study
intervention; or expected to require any live vaccines during study period.

8. Evidence at the initial screening visit of active or prior hepatitis B infection based
on serological tests for hepatitis B surface antigen (HbsAg).

9. Positive serological tests for human immunodeficiency virus (HIV) antibody and/or
hepatitis C virus (HCV) antibody at the initial screening visit.

10. Blood donation of >400 mL within 3 months before screening or >200 mL within 4 weeks
before screening or plan to donate blood during study period.

11. Acute or febrile illness within 7 days prior to the first dose of study intervention
or participants with evidence of active infection.

12. Evidence of an active or suspected cancer or a history of malignancy within the
previous 3 years, except for the following, which did not require systemic therapy and
are considered cured: nonmelanoma skin cancer, curatively treated localized prostate
cancer, or other in situ cancer.

13. History of drug abuse or a positive drug abuse test result at screening or D-1.

14. History of alcohol abuse or a positive alcohol test result at screening or D-1.

15. Use of prescription medications or herbal remedies within 14 days or 5 elimination
half-lives (whichever is longer) of study intervention administration or use of over
the counter (OTC) drugs within 7 days of study intervention administration (apart from
recommended doses of vitamin/mineral supplements, OTC analgesics, or other agents that
have been discussed with and approved by the Investigator and Sponsor). Participants
who used recommended doses of paracetamol/ibuprofen for acute conditions (e.g.,
headache) will not be excluded. Participants who have been on hormone replacement
therapy (HRT) or oral contraception for a period of at least 2 months prior to the
start of screening will not be excluded from the study, provided the contraceptive or
HRT regimen will remain unchanged during the conduct of the study.

16. Use of any known liver enzyme inducer or liver enzyme inhibiting food or beverage
(such as all citrus fruits including tangerine, grapefruit, sweet orange, lime,
kumquat, citron, orange, lemon, etc., and fruit juices) within 7 days prior to
administration.

17. Any major surgery within 6 months before screening, or plan to have a surgery during
the study period.

18. Any other conditions that the Investigator considers may affect the participants'
informed consent or adherence to the study protocol, completion of the test according
to the study procedure, or the participants' participation in the test may affect the
test results or their own safety.

19. Receipt of another study intervention within 1 month or 5 elimination half-lives
(whichever is longer) prior to administration of the study intervention.

20. Abnormal cardiac conditions and ECG:

i. The Fridericia algorithm corrected QT interval (QTcF) of ECG during screening
period is >450 ms for males and >470 ms for females or is considered abnormal with
clinical significance as determined by the Investigator.

ii. Sustained (ie, 3 independent measurements within 30 minutes) HR (pulse) >100 or
<40 bpm.

iii. Personal and/or family history of congenital long QT syndrome or sudden cardiac
death.

21. Pregnant (positive blood or urine pregnancy test at the initial screening visit or
D-1).

22. Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or
child) who is investigational site or Sponsor staff directly involved with this study.

23. Unwilling to abstain from smoking or vaping and the consumption of any caffeine or
alcohol-containing food or drinks that may influence the drug metabolism from 72 hours
before administration to discharge.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/03/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
29/11/2023
Sample size
Target
Accrual to date
Final
76
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX Clinical Research - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
SciNeuro
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
SNP318 is developed to treat neurodegenerative diseases including Alzheimer's disease. In the
current phase 1 study, the IP is tested in healthy volunteers, and the purpose is to
investigate the safety, tolerability, and PK of single and multiple ascending oral doses of
SNP318.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05792163
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05792163